



Doxercalciferol

Catalog No: tcsc0395

Z	Available Sizes
Size:	2mg
Size:	5mg
Size:	10mg
Size:	25mg
Size:	50mg
Size:	100mg
	Specifications
CAS N 54573	
Form	
Pathy Vitam	way: in D Related
Targe	
Purity >98%	y / Grade:
Solub	oility: 1 in DMSO
	native Names: naHydroxyvitamin D2





Observed Molecular Weight:

412.65

Product Description

Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevent renal disease.

IC50 & Target: Vitamin D receptor^[1]

In Vivo: Doxercalciferol (0.083, 0.167 or 0.333 μg/kg, i.p.) elevates serum phosphorus at Week 6 in 5/6 nephrectomized (NX) rats. Doxercalciferol (0.167 and 0.333 μg/kg) also increases serum calcium and Ca \times P at Weeks 2 and 6, and enhances increased pulse wave velocity (PWV) at Week 6 in 5/6 nephrectomized (NX) rats. Doxercalciferol blocks PTH from rising at 0.083 μg/kg, and lowers serum PTH to the SHAM level [1]. Doxercalciferol (125 ng/kg, i.p. thrice per week) increases expression of VDR mRNA level and renal expression of TRPV5 in NON mice fed a HF diet. Doxercalciferol also improves proteinuria, prevents loss of podocytes, and accumulation of extracellular matrix proteins in HF diet-induced mice. Doxercalciferol inhibits the expression of profibrotic growth factors (TGF-β, PAI-1, and connective tissue growth factor (CTGF)), and blocks increased expression of the renin-angiotensin-aldosterone system in mice fed a HF diet. Furthermore, Doxercalciferol suppresses macrophage infiltration, decreases NF-kb activity, and preventes expression of proinflammatory cytokine and the increase in renal lipid accumulation in mice fed a HF diet $^{[2]}$. Doxercalciferol (30 ng/kg, i.p. thrice per week) prevents albuminuria, markedly attenuates podocyte loss and apoptosis, and reduces glomerular fibrosis in streptozotocin-induced diabetic mice $^{[3]}$.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!